Financial Support – LYNPARZA® (olaparib)
PDF) Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib
Clinical trials appendix Q3 2018 results update
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours | SpringerLink
206162Orig1s000
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Australian public assessment for Olaparib
Australian Public Assessment Report for Olaparib
How To Take LYNPARZA® (olaparib)
PDF) Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations: PBPK modeling for olaparib dosing recommendations
How To Take LYNPARZA® (olaparib)
Lynparza, INN-olaparib
PDF) Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations: PBPK modeling for olaparib dosing recommendations
Efamat Efavirenz 600MG Tablets Exporter, Manufacturer
Australian public assessment for Olaparib
PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health
Lynparza, INN - olaparib
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library
Lynparza, INN - olaparib
Investor science event: Late-stage pipeline webcast
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library
How To Take LYNPARZA® (olaparib)
Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies
Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials - Radiotherapy and Oncology
